Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis
Rojo A. Ratsimandresy, Emma Doran, Hart S. Dengler…·Mark S. Wilson
This study shows that blocking OSM and IL-6 reduces fibrosis and inflammation in pulmonary fibrosis by targeting their shared receptor and distinct pathways.